Arlington Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Arlington Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$357K	Hold	800	–	–	0.2%	68
2025 Q4	$363K	Buy	+800	New	+$345K	0.22%	61
2015 Q3	–	Sell	-30,797	Closed	-$3.82M	–	31
2015 Q2	$3.82M	Buy	30,797 +2,696	+10%	+$340K	2.56%	10
2015 Q1	$3.31M	Buy	28,101 +2,557	+10%	+$306K	2.37%	12
2014 Q4	$3.04M	Buy	+25,544	New	+$2.88M	2.57%	10

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Arlington Capital Management's VRTX Position: Q1 2026 in Review

Arlington Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 800 shares worth $357K. The position accounts for 0.2% of the portfolio, ranked #68.

Arlington Capital Management first reported a position in VRTX in Q4 2014 and has held it in 5 quarters since. The position peaked at $3.82M in Q2 2015. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Arlington Capital Management held 800 shares of Vertex Pharmaceuticals worth $357K as of Q1 2026.
Arlington Capital Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.2% of Arlington Capital Management's portfolio in Q1 2026, its #68 holding.
Arlington Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 5 quarters since.
Arlington Capital Management's Vertex Pharmaceuticals position peaked at $3.82M in Q2 2015.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Arlington Capital Management's 13F filing for Q1 2026, filed 1 May 2026.